Meeting News

Vascular intervention highlights from VIVA 18

This year at VIVA 18, the focus was on new advances for vascular intervention. Cardiology Today’s Intervention was onsite at VIVA 18 in Las Vegas, where topics discussed ranged from medical therapies for peripheral artery disease to new drug-coated balloons to peripheral stents.

This list features the most-read articles from VIVA 18 on Healio.com/Intervention.

 

Medical therapies provide options for PAD treatment

In recent years, data have emerged showing a variety of medical therapies can improve outcomes of patients with peripheral artery disease, according to a session dedicated to pharmacotherapy at VIVA 18. This article provides an update on new data and optimal use of antiplatelet therapy, rivaroxaban (Xarelto, Janssen), vorapaxar (Zontivity, Aralez), PCSK9 inhibitors and cilostazol in patients with PAD. Read more

 

Implant successfully repairs dissections caused by angioplasty

An endovascular implant (Tack Endovascular System, Intact Vascular) used to repair dissections caused by plain or drug-coated balloons during angioplasty in peripheral procedures was associated with positive outcomes in the TOBA II trial. Read more

 

SENTRY: Use of bioconvertible IVC filter safe, effective at 2 years

Use of a bioconvertible inferior vena cava filter (Sentry, BTG/Novate Medical) in patients with pulmonary embolism conferred few adverse events and a high bioconversion rate at 2 years, according to findings from the SENTRY study. Read more

 

Peripheral stent confers good outcomes in CFA disease

A peripheral stent (Supera Peripheral Vascular Mimetic Implant Device, Abbott Vascular) was safe and effective for the treatment of common femoral artery lesions at 12 months. Read more

 

DCB shows benefit at 6 months for below-the-knee lesions

New data from the Lutonix BTK study highlighted superior efficacy and similar safety through 6 months with a drug-coated balloon (Lutonix 014), compared with standard balloon angioplasty, for treatment of narrowed or obstructed arteries below the knee. Read more

 

DCB remains superior to PTA at 5 years

A drug-coated balloon (IN.PACT Admiral, Medtronic) conferred a lower rate of clinically driven target lesion revascularization at 5 years compared with percutaneous transluminal angioplasty in patients with peripheral artery disease, according to final results of the IN.PACT SFA study. Read more

 

VERNACULAR: Venous stent confers patency benefit at 1 year

A venous stent (Venovo, BD) was associated with high rates of primary patency and low rates of target lesion revascularization for the treatment of iliac and femoral vein occlusive disease. Read more

This year at VIVA 18, the focus was on new advances for vascular intervention. Cardiology Today’s Intervention was onsite at VIVA 18 in Las Vegas, where topics discussed ranged from medical therapies for peripheral artery disease to new drug-coated balloons to peripheral stents.

This list features the most-read articles from VIVA 18 on Healio.com/Intervention.

 

Medical therapies provide options for PAD treatment

In recent years, data have emerged showing a variety of medical therapies can improve outcomes of patients with peripheral artery disease, according to a session dedicated to pharmacotherapy at VIVA 18. This article provides an update on new data and optimal use of antiplatelet therapy, rivaroxaban (Xarelto, Janssen), vorapaxar (Zontivity, Aralez), PCSK9 inhibitors and cilostazol in patients with PAD. Read more

 

Implant successfully repairs dissections caused by angioplasty

An endovascular implant (Tack Endovascular System, Intact Vascular) used to repair dissections caused by plain or drug-coated balloons during angioplasty in peripheral procedures was associated with positive outcomes in the TOBA II trial. Read more

 

SENTRY: Use of bioconvertible IVC filter safe, effective at 2 years

Use of a bioconvertible inferior vena cava filter (Sentry, BTG/Novate Medical) in patients with pulmonary embolism conferred few adverse events and a high bioconversion rate at 2 years, according to findings from the SENTRY study. Read more

 

Peripheral stent confers good outcomes in CFA disease

A peripheral stent (Supera Peripheral Vascular Mimetic Implant Device, Abbott Vascular) was safe and effective for the treatment of common femoral artery lesions at 12 months. Read more

 

DCB shows benefit at 6 months for below-the-knee lesions

New data from the Lutonix BTK study highlighted superior efficacy and similar safety through 6 months with a drug-coated balloon (Lutonix 014), compared with standard balloon angioplasty, for treatment of narrowed or obstructed arteries below the knee. Read more

 

DCB remains superior to PTA at 5 years

A drug-coated balloon (IN.PACT Admiral, Medtronic) conferred a lower rate of clinically driven target lesion revascularization at 5 years compared with percutaneous transluminal angioplasty in patients with peripheral artery disease, according to final results of the IN.PACT SFA study. Read more

 

VERNACULAR: Venous stent confers patency benefit at 1 year

A venous stent (Venovo, BD) was associated with high rates of primary patency and low rates of target lesion revascularization for the treatment of iliac and femoral vein occlusive disease. Read more

    See more from VIVA